Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience.
Neuroendocrine neoplasms
Neuroendocrine tumors
Peptide receptor radionuclide therapy
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
accepted:
05
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
The available data for the safety and efficacy of repeat peptide receptor radionuclide therapy (PRRT) are almost exclusively from European centers. We present an updated experience with repeat PRRT in a cohort of US patients with neuroendocrine tumors (NETs) at our NET center of excellence. We used our single-center longitudinal NET registry to identify patients who had been previously treated with at least one dose of PRRT (PRRT 1, either A total of 11 patients were included in the analysis. 45.5% (5/11) of patients received We show that repeat PRRT may benefit select patients and have an acceptable safety profile. In our cohort, PFS was significantly lower after PRRT2 as compared to PRRT1.
Identifiants
pubmed: 38780680
doi: 10.1007/s12029-024-01065-z
pii: 10.1007/s12029-024-01065-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018;31(12):1770–86.
doi: 10.1038/s41379-018-0110-y
pubmed: 30140036
pmcid: 6265262
Strosberg JR, Caplin ME, Kunz PL, et al.
doi: 10.1016/S1470-2045(21)00572-6
pubmed: 34793718
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with
doi: 10.1200/JCO.2018.78.5865
pubmed: 29878866
pmcid: 6366953
Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [
doi: 10.1158/1078-0432.CCR-16-2743
pubmed: 28428192
Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839–68.
doi: 10.6004/jnccn.2021.0032
pubmed: 34340212
Hope TA, Bodei L, Chan JA, et al. NANETS/SNMMI consensus statement on patient selection and appropriate use of
doi: 10.2967/jnumed.119.240911
pubmed: 32015164
pmcid: 9364765
Del Rivero J, Perez K, Kennedy EB, et al. Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO Guideline. J Clin Oncol. 2023;41(32):5049–67.
doi: 10.1200/JCO.23.01529
pubmed: 37774329
Hicks RJ, Kwekkeboom DJ, Krenning E, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309.
doi: 10.1159/000475526
pubmed: 28402980
Prentice RL, Williams BJ, Peterson AV. On the regression analysis of multivariate failure time data. Biometrika. 1981;68:373–9.
doi: 10.1093/biomet/68.2.373
van der Zwan WA, Brabander T, Kam BLR, et al. Salvage peptide receptor radionuclide therapy with [
doi: 10.1007/s00259-018-4158-1
pubmed: 30267116
Rudisile S, Gosewisch A, Wenter V, et al. Salvage PRRT with
doi: 10.1186/s12885-019-6000-y
pubmed: 31395036
pmcid: 6686531
Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis [published correction appears in Cancer Treat Rev. 2021 Jun 97:102203]. Cancer Treat Rev. 2021;93:102141.
doi: 10.1016/j.ctrv.2020.102141
pubmed: 33418096
Zemczak A, Gut P, Pawlak D, et al. The safety and efficacy of the repeated PRRT with [
doi: 10.1155/2021/6615511
pubmed: 33552155
pmcid: 7847334
Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5–19.
doi: 10.1007/s00259-014-2893-5
pubmed: 25273832
Sabet A, Ezziddin K, Pape UF, et al. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013;54(11):1857–61.
doi: 10.2967/jnumed.112.119347
pubmed: 24009272
Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26(11):1439–47.
doi: 10.1007/s002590050476
pubmed: 10552085
Shi M, Jakobsson V, Greifenstein L, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022;9:1034315.
doi: 10.3389/fmed.2022.1034315
pubmed: 36569154